CA Sumit Mangla
@sumit_7320
Delhi
7+ Years of experience
SEBI Registration INH000028626WELCOME TO TRADING WITH CA SUMIT MANGLA - SEBI REGISTERED RESEARCH ANALYST Registration No. INH000028626 We provide professional trading calls across multiple segments: 1. Indices – Intraday Option Buying & Selling 2. F&O Stocks – Intraday Futures, Intraday Option Selling & BTST Futures 3. Cash Stocks – Intraday & ... Read more
Trade Ideas
259
Opinions
219
Followers
596
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 6 hours ago
Alkem Labs initiates forensic audit on fund misappropriation
ALKEM
Alkem Laboratories Limited (ALKEM) has approved the initiation of a forensic audit. The Audit Committee approved the move on 21 October 2026 in connection with alleged misappropriation of funds by a former employee.
The forensic audit has been initiated to examine the facts and circumstances relating to the incident. It will determine the root cause of the incident and recommend appropriate corrective measures. The disclosure was made under Regulation 30 of SEBI (LODR) Regulations.
The key trigger is the initiation of a forensic audit into alleged misappropriation of funds by a former employee, which highlights internal control and governance aspects. While the quantum and materiality are not yet known, such announcements can create near-term uncertainty. Peers in the pharmaceutical space such as Sun Pharmaceutical, Cipla, and Lupin may face comparison on governance standards and internal controls. Near-term prices could see a negative reaction until clarity emerges on the financial impact and findings. Risks include any material financial loss, regulatory scrutiny, or delays in completing the audit. Competitors listed: Sun Pharmaceutical, Cipla, Lupin. shared an insight ⚡️ 9 hours ago
Nestle India announces senior management changes wef Jan 27
NESTLEIND
Nestle India Limited (NESTLEIND) has announced changes in its senior management as part of an internal re-organisation. The changes will be effective from 1 January 2027.
Mr. Gopichandar Jagatheesan has been appointed as Business Executive Officer (BEO) – Nutrition and Dairy. Ms. Mansi Khanna has been appointed as BEO – Chocolates and Confectionery. Mr. Vineet Singh will move to a role with a Nestlé affiliate. The changes are pursuant to internal re-organisation.
The key trigger is the internal re-organisation of leadership roles in the Nutrition and Dairy, and Chocolates and Confectionery businesses. Such moves are routine for large FMCG companies and are unlikely to materially alter the overall business trajectory in the near term. Peers such as Britannia Industries, Hindustan Unilever, and ITC may face comparison on leadership stability and portfolio management. Near-term prices are expected to remain largely unaffected by the announcement. Risks include any temporary disruption during the transition period or delays in the effective implementation of the changes. Competitors listed: Britannia Industries, Hindustan Unilever, ITC shared an insight ⚡️ 15 hours ago
Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.
JUBLPHARMA
Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore.
The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned.
The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.FAQ's
What are the top stock recommendations by CA Sumit Mangla?
CA Sumit Mangla regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Panama Petrochem Ltd. (Bullish), ALKEM, NESTLEIND and JUBLPHARMA. Explore CA Sumit Mangla's complete list of posts and trade views on their StockGro profile.
How can I follow CA Sumit Mangla's latest investment insights?
You can follow CA Sumit Mangla's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is CA Sumit Mangla's investment strategy?
CA Sumit Mangla follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has CA Sumit Mangla been a SEBI-registered Research Analyst (RA)?
CA Sumit Mangla has been a SEBI-registered Research Analyst and have 7+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see CA Sumit Mangla's past performance and stock picks?
You can check CA Sumit Mangla's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact CA Sumit Mangla for stock market advice?
For stock market guidance from CA Sumit Mangla, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is CA Sumit Mangla's track record in predicting market movements?
CA Sumit Mangla has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for CA Sumit Mangla?
CA Sumit Mangla is a SEBI-registered Research Analyst with the SEBI Registration INH000028626. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro